Search the database for deliberate release of GM medicinal products
Displaying 1 - 2 of 2
| EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
|---|---|---|---|---|
| B/BE/11/BVW1 | A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC) | Transgene | Humans | sequences coding for human mucine 1 (MUC1) antigen and interleukin-2 (IL2) |
| Only notified under the "contained use" procedure. Dossier submitted on . | Phase II randomized study of immunotherapy of advanced breast cancer by repeated intramuscular injection of a recombinant vaccinia virus containing sequences coding for human MUC-1 and interleukin-2 (TG1031) comparing two doses levels | Transgene | Humans | Muc-1 and Interleukine 2 (IL-2) |